ID   PHLP1_HUMAN             Reviewed;        1717 AA.
AC   O60346; A1A4F5; Q641Q7; Q6P4C4; Q6PJI6; Q86TN6; Q96FK2; Q9NUY1;
DT   07-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 3.
DT   12-APR-2017, entry version 162.
DE   RecName: Full=PH domain leucine-rich repeat-containing protein phosphatase 1;
DE            EC=3.1.3.16;
DE   AltName: Full=Pleckstrin homology domain-containing family E member 1;
DE            Short=PH domain-containing family E member 1;
DE   AltName: Full=Suprachiasmatic nucleus circadian oscillatory protein;
DE            Short=hSCOP;
GN   Name=PHLPP1; Synonyms=KIAA0606, PHLPP, PLEKHE1, SCOP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16177791; DOI=10.1038/nature03983;
RA   Nusbaum C., Zody M.C., Borowsky M.L., Kamal M., Kodira C.D.,
RA   Taylor T.D., Whittaker C.A., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Yang X., Abouelleil A., Allen N.R., Anderson S.,
RA   Bloom T., Bugalter B., Butler J., Cook A., DeCaprio D., Engels R.,
RA   Garber M., Gnirke A., Hafez N., Hall J.L., Norman C.H., Itoh T.,
RA   Jaffe D.B., Kuroki Y., Lehoczky J., Lui A., Macdonald P., Mauceli E.,
RA   Mikkelsen T.S., Naylor J.W., Nicol R., Nguyen C., Noguchi H.,
RA   O'Leary S.B., Piqani B., Smith C.L., Talamas J.A., Topham K.,
RA   Totoki Y., Toyoda A., Wain H.M., Young S.K., Zeng Q., Zimmer A.R.,
RA   Fujiyama A., Hattori M., Birren B.W., Sakaki Y., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 18.";
RL   Nature 437:551-555(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 349-1717.
RC   TISSUE=Brain;
RX   PubMed=9628581; DOI=10.1093/dnares/5.1.31;
RA   Nagase T., Ishikawa K., Miyajima N., Tanaka A., Kotani H., Nomura N.,
RA   Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. IX.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 5:31-39(1998).
RN   [3]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 475-1717.
RC   TISSUE=Cerebellum, Hippocampus, Lymphoma, Melanoma, and
RC   Retinoblastoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 495-1233.
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   FUNCTION, ENZYME ACTIVITY, COFACTOR, ENZYME REGULATION, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF 1715-THR--LEU-1717.
RX   PubMed=15808505; DOI=10.1016/j.molcel.2005.03.008;
RA   Gao T., Furnari F., Newton A.C.;
RT   "PHLPP: a phosphatase that directly dephosphorylates Akt, promotes
RT   apoptosis, and suppresses tumor growth.";
RL   Mol. Cell 18:13-24(2005).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, ALTERNATIVE SPLICING, AND INTERACTION
RP   WITH AKT2 AND AKT3.
RX   PubMed=17386267; DOI=10.1016/j.molcel.2007.02.017;
RA   Brognard J., Sierecki E., Gao T., Newton A.C.;
RT   "PHLPP and a second isoform, PHLPP2, differentially attenuate the
RT   amplitude of Akt signaling by regulating distinct Akt isoforms.";
RL   Mol. Cell 25:917-931(2007).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH PRKCB.
RX   PubMed=18162466; DOI=10.1074/jbc.M707319200;
RA   Gao T., Brognard J., Newton A.C.;
RT   "The phosphatase PHLPP controls the cellular levels of protein kinase
RT   C.";
RL   J. Biol. Chem. 283:6300-6311(2008).
RN   [10]
RP   INTERACTION WITH FKBP5; AKT2 AND AKT3.
RX   PubMed=19732725; DOI=10.1016/j.ccr.2009.07.016;
RA   Pei H., Li L., Fridley B.L., Jenkins G.D., Kalari K.R., Lingle W.,
RA   Petersen G., Lou Z., Wang L.;
RT   "FKBP51 affects cancer cell response to chemotherapy by negatively
RT   regulating Akt.";
RL   Cancer Cell 16:259-266(2009).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=19079341; DOI=10.1038/onc.2008.450;
RA   Liu J., Weiss H.L., Rychahou P., Jackson L.N., Evers B.M., Gao T.;
RT   "Loss of PHLPP expression in colon cancer: role in proliferation and
RT   tumorigenesis.";
RL   Oncogene 28:994-1004(2009).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH STK4.
RX   PubMed=20513427; DOI=10.1016/j.molcel.2010.03.017;
RA   Qiao M., Wang Y., Xu X., Lu J., Dong Y., Tao W., Stein J., Stein G.S.,
RA   Iglehart J.D., Shi Q., Pardee A.B.;
RT   "Mst1 is an interacting protein that mediates PHLPPs' induced
RT   apoptosis.";
RL   Mol. Cell 38:512-523(2010).
RN   [13]
RP   INTERACTION WITH SCRIB.
RX   PubMed=21701506; DOI=10.1038/embor.2011.106;
RA   Li X., Yang H., Liu J., Schmidt M.D., Gao T.;
RT   "Scribble-mediated membrane targeting of PHLPP1 is required for its
RT   negative regulation of Akt.";
RL   EMBO Rep. 12:818-824(2011).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH RPS6KB1.
RX   PubMed=21986499; DOI=10.1128/MCB.05799-11;
RA   Liu J., Stevens P.D., Li X., Schmidt M.D., Gao T.;
RT   "PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation
RT   and cell growth.";
RL   Mol. Cell. Biol. 31:4917-4927(2011).
RN   [15]
RP   INTERACTION WITH SLC9A3R1.
RX   PubMed=21804599; DOI=10.1038/onc.2011.324;
RA   Molina J.R., Agarwal N.K., Morales F.C., Hayashi Y., Aldape K.D.,
RA   Cote G., Georgescu M.M.;
RT   "PTEN, NHERF1 and PHLPP form a tumor suppressor network that is
RT   disabled in glioblastoma.";
RL   Oncogene 31:1264-1274(2012).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [17]
RP   INTERACTION WITH WDR48 AND USP12, AND ENZYME REGULATION.
RX   PubMed=24145035; DOI=10.1074/jbc.M113.503383;
RA   Gangula N.R., Maddika S.;
RT   "WD repeat protein WDR48 in complex with deubiquitinase USP12
RT   suppresses Akt-dependent cell survival signaling by stabilizing PH
RT   domain leucine-rich repeat protein phosphatase 1 (PHLPP1).";
RL   J. Biol. Chem. 288:34545-34554(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-317 AND SER-412, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND COFACTOR.
RX   PubMed=24892992; DOI=10.1021/bi500428j;
RA   Sierecki E., Newton A.C.;
RT   "Biochemical characterization of the phosphatase domain of the tumor
RT   suppressor PH domain leucine-rich repeat protein phosphatase.";
RL   Biochemistry 53:3971-3981(2014).
RN   [20]
RP   FUNCTION, AND INTERACTION WITH RAF1.
RX   PubMed=24530606; DOI=10.1053/j.gastro.2014.02.003;
RA   Li X., Stevens P.D., Liu J., Yang H., Wang W., Wang C., Zeng Z.,
RA   Schmidt M.D., Yang M., Lee E.Y., Gao T.;
RT   "PHLPP is a negative regulator of RAF1, which reduces colorectal
RT   cancer cell motility and prevents tumor progression in mice.";
RL   Gastroenterology 146:1301-1310(2014).
RN   [21]
RP   INTERACTION WITH BRAP.
RX   PubMed=25820252; DOI=10.1038/srep09459;
RA   Fatima S., Wagstaff K.M., Loveland K.L., Jans D.A.;
RT   "Interactome of the negative regulator of nuclear import BRCA1-binding
RT   protein 2.";
RL   Sci. Rep. 5:9459-9459(2015).
CC   -!- FUNCTION: Protein phosphatase involved in regulation of Akt and
CC       PKC signaling. Mediates dephosphorylation in the C-terminal domain
CC       hydrophobic motif of members of the AGC Ser/Thr protein kinase
CC       family; specifically acts on 'Ser-473' of AKT2 and AKT3, 'Ser-660'
CC       of PRKCB and 'Ser-657' of PRKCA (PubMed:15808505, PubMed:17386267,
CC       PubMed:18162466). Isoform 2 seems to have a major role in
CC       regulating Akt signaling in hippocampal neurons (By similarity).
CC       Akt regulates the balance between cell survival and apoptosis
CC       through a cascade that primarily alters the function of
CC       transcription factors that regulate pro- and antiapoptotic genes.
CC       Dephosphorylation of 'Ser-473' of Akt triggers apoptosis and
CC       suppression of tumor growth. Dephosphorylation of PRKCA and PRKCB
CC       leads to their destabilization and degradation (PubMed:18162466).
CC       Dephosphorylates STK4 on 'Thr-387' leading to STK4 activation and
CC       apoptosis (PubMed:20513427). Dephosphorylates RPS6KB1 and is
CC       involved in regulation of cap-dependent translation
CC       (PubMed:21986499). Inhibits cancer cell proliferation and may act
CC       as a tumor suppressor (PubMed:19079341). Dephosphorylates RAF1
CC       inhibiting its kinase activity (PubMed:24530606). May act as a
CC       negative regulator of K-Ras signaling in membrane rafts (By
CC       similarity). Involved in the hippocampus-dependent long-term
CC       memory formation (By similarity). Involved in circadian control by
CC       regulating the consolidation of circadian periodicity after
CC       resetting (By similarity). Involved in development and function of
CC       regulatory T-cells (By similarity). {ECO:0000250|UniProtKB:Q8CHE4,
CC       ECO:0000250|UniProtKB:Q9WTR8, ECO:0000269|PubMed:15808505,
CC       ECO:0000269|PubMed:17386267, ECO:0000269|PubMed:18162466,
CC       ECO:0000269|PubMed:19079341, ECO:0000269|PubMed:21986499,
CC       ECO:0000269|PubMed:24530606}.
CC   -!- CATALYTIC ACTIVITY: [a protein]-serine/threonine phosphate + H(2)O
CC       = [a protein]-serine/threonine + phosphate.
CC       {ECO:0000269|PubMed:15808505, ECO:0000269|PubMed:24892992}.
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC       Note=Binds 2 manganese ions per subunit (By similarity). Mn(2+) is
CC       inhibitory below pH 8 and activating above pH 8 (PubMed:24892992).
CC       {ECO:0000250, ECO:0000269|PubMed:24892992};
CC   -!- ENZYME REGULATION: Insensitive to okadaic acid (PubMed:15808505).
CC       Deubiquitination by WDR48-USP12 complex positively regulates
CC       PHLPP1 stability (PubMed:24145035). {ECO:0000269|PubMed:15808505,
CC       ECO:0000269|PubMed:24145035}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1.5 mM for p-nitrophenyl phosphate
CC         {ECO:0000269|PubMed:24892992};
CC   -!- SUBUNIT: Interacts with the nucleotide free form of K-Ras (KRAS)
CC       via its LRR repeats (By similarity). Interacts with AKT2, AKT3,
CC       PRKCB isoform beta-II, STK4, RPS6KB1, RAF1 (PubMed:17386267,
CC       PubMed:18162466, PubMed:19732725, PubMed:21986499,
CC       PubMed:24530606). Isoform 1 (predominantly) and isoform 2 interact
CC       with BRAP (PubMed:25820252). Interacts with FKBP5; FKBP5 acts as a
CC       scaffold for PHLPP1 and Akt (PubMed:19732725). Interacts with
CC       SCRIB; SCRIB acts as a scaffold for PHLPP1 and Akt
CC       (PubMed:21701506). Interacts with SLC9A3R1; SLC9A3R1 scaffolds a
CC       heterotrimeric complex with PTEN at the plasma membrane
CC       (PubMed:21804599). Interacts with WDR48 and USP12
CC       (PubMed:24145035). {ECO:0000250|UniProtKB:Q9WTR8,
CC       ECO:0000269|PubMed:17386267, ECO:0000269|PubMed:18162466,
CC       ECO:0000269|PubMed:19732725, ECO:0000269|PubMed:20513427,
CC       ECO:0000269|PubMed:21701506, ECO:0000269|PubMed:21804599,
CC       ECO:0000269|PubMed:21986499, ECO:0000269|PubMed:24145035,
CC       ECO:0000269|PubMed:24530606, ECO:0000269|PubMed:25820252}.
CC   -!- INTERACTION:
CC       P05771-2:PRKCB; NbExp=5; IntAct=EBI-2511516, EBI-5774511;
CC       Q14160:SCRIB; NbExp=2; IntAct=EBI-2511516, EBI-357345;
CC       Q80U72:Scrib (xeno); NbExp=2; IntAct=EBI-2511516, EBI-1766028;
CC       O14745:SLC9A3R1; NbExp=5; IntAct=EBI-11165225, EBI-349787;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Membrane; Peripheral membrane
CC       protein. Nucleus. Note=In colorectal cancer tissue, expression is
CC       concentrated at the lateral membrane of epithelial cells.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cell membrane
CC       {ECO:0000269|PubMed:21804599}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=beta;
CC         IsoId=O60346-1; Sequence=Displayed;
CC       Name=2; Synonyms=alpha;
CC         IsoId=O60346-2; Sequence=VSP_057809;
CC   -!- TISSUE SPECIFICITY: In colorectal cancer tissue, expression is
CC       highest in the surface epithelium of normal colonic mucosa
CC       adjacent to the cancer tissue but is largely excluded from the
CC       crypt bases. Expression is lost or significantly decreased in 78%
CC       of tested tumors (at protein level). Ubiquitously expressed in
CC       non-cancerous tissues. {ECO:0000269|PubMed:15808505,
CC       ECO:0000269|PubMed:19079341}.
CC   -!- DOMAIN: The PH domain is required for interaction with PRKCB and
CC       its dephosphorylation.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH14927.3; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAH82244.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAI26278.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=BAA91980.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PHLPP1ID44544ch18q21.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AC015989; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC022046; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC027553; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB011178; BAA25532.2; -; mRNA.
DR   EMBL; BC010706; AAH10706.1; -; mRNA.
DR   EMBL; BC014927; AAH14927.3; ALT_INIT; mRNA.
DR   EMBL; BC047653; AAH47653.1; -; mRNA.
DR   EMBL; BC063519; AAH63519.1; -; mRNA.
DR   EMBL; BC082244; AAH82244.1; ALT_SEQ; mRNA.
DR   EMBL; BC126277; AAI26278.1; ALT_INIT; mRNA.
DR   EMBL; AK001924; BAA91980.1; ALT_INIT; mRNA.
DR   CCDS; CCDS45881.2; -. [O60346-1]
DR   PIR; T00258; T00258.
DR   RefSeq; NP_919431.2; NM_194449.3. [O60346-1]
DR   UniGene; Hs.465337; -.
DR   ProteinModelPortal; O60346; -.
DR   BioGrid; 116843; 33.
DR   IntAct; O60346; 31.
DR   MINT; MINT-2796653; -.
DR   STRING; 9606.ENSP00000262719; -.
DR   BindingDB; O60346; -.
DR   ChEMBL; CHEMBL3414405; -.
DR   DEPOD; O60346; -.
DR   iPTMnet; O60346; -.
DR   PhosphoSitePlus; O60346; -.
DR   BioMuta; PHLPP1; -.
DR   EPD; O60346; -.
DR   MaxQB; O60346; -.
DR   PaxDb; O60346; -.
DR   PeptideAtlas; O60346; -.
DR   PRIDE; O60346; -.
DR   Ensembl; ENST00000262719; ENSP00000262719; ENSG00000081913. [O60346-1]
DR   GeneID; 23239; -.
DR   KEGG; hsa:23239; -.
DR   UCSC; uc021ule.2; human. [O60346-1]
DR   CTD; 23239; -.
DR   DisGeNET; 23239; -.
DR   GeneCards; PHLPP1; -.
DR   H-InvDB; HIX0014494; -.
DR   H-InvDB; HIX0174202; -.
DR   HGNC; HGNC:20610; PHLPP1.
DR   HPA; HPA020200; -.
DR   MIM; 609396; gene.
DR   neXtProt; NX_O60346; -.
DR   OpenTargets; ENSG00000081913; -.
DR   PharmGKB; PA165429055; -.
DR   eggNOG; KOG0619; Eukaryota.
DR   eggNOG; COG0631; LUCA.
DR   eggNOG; COG4886; LUCA.
DR   GeneTree; ENSGT00440000037833; -.
DR   InParanoid; O60346; -.
DR   KO; K16340; -.
DR   OMA; FTNGSRV; -.
DR   OrthoDB; EOG091G03A3; -.
DR   PhylomeDB; O60346; -.
DR   TreeFam; TF315993; -.
DR   Reactome; R-HSA-199418; Negative regulation of the PI3K/AKT network.
DR   SIGNOR; O60346; -.
DR   ChiTaRS; PHLPP1; human.
DR   GeneWiki; PHLPP_(gene); -.
DR   GenomeRNAi; 23239; -.
DR   PRO; PR:O60346; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   Bgee; ENSG00000081913; -.
DR   CleanEx; HS_PHLPP; -.
DR   ExpressionAtlas; O60346; baseline and differential.
DR   Genevisible; O60346; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031965; C:nuclear membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004722; F:protein serine/threonine phosphatase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0009649; P:entrainment of circadian clock; IEA:Ensembl.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IMP:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:1900744; P:regulation of p38MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0090036; P:regulation of protein kinase C signaling; IBA:GO_Central.
DR   GO; GO:0002667; P:regulation of T cell anergy; IEA:Ensembl.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.60.40.10; -; 1.
DR   Gene3D; 3.80.10.10; -; 5.
DR   InterPro; IPR032675; L_dom-like.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR001932; PPM-type_phosphatase_dom.
DR   Pfam; PF13516; LRR_6; 2.
DR   Pfam; PF13855; LRR_8; 2.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF00481; PP2C; 1.
DR   SMART; SM00369; LRR_TYP; 10.
DR   SMART; SM00332; PP2Cc; 1.
DR   SUPFAM; SSF50729; SSF50729; 2.
DR   SUPFAM; SSF52058; SSF52058; 2.
DR   SUPFAM; SSF81606; SSF81606; 1.
DR   PROSITE; PS51450; LRR; 17.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS51746; PPM_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Apoptosis; Cell membrane;
KW   Complete proteome; Cytoplasm; Hydrolase; Leucine-rich repeat;
KW   Manganese; Membrane; Metal-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Protein phosphatase; Reference proteome; Repeat;
KW   Tumor suppressor.
FT   CHAIN         1   1717       PH domain leucine-rich repeat-containing
FT                                protein phosphatase 1.
FT                                /FTId=PRO_0000057781.
FT   DOMAIN      536    636       PH. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   REPEAT      638    659       LRR 1.
FT   REPEAT      661    682       LRR 2.
FT   REPEAT      692    712       LRR 3.
FT   REPEAT      715    736       LRR 4.
FT   REPEAT      738    760       LRR 5.
FT   REPEAT      761    783       LRR 6.
FT   REPEAT      784    804       LRR 7.
FT   REPEAT      808    831       LRR 8.
FT   REPEAT      832    853       LRR 9.
FT   REPEAT      873    894       LRR 10.
FT   REPEAT      895    916       LRR 11.
FT   REPEAT      918    939       LRR 12.
FT   REPEAT      941    962       LRR 13.
FT   REPEAT      963    984       LRR 14.
FT   REPEAT      987   1008       LRR 15.
FT   REPEAT     1013   1033       LRR 16.
FT   REPEAT     1037   1058       LRR 17.
FT   REPEAT     1061   1082       LRR 18.
FT   REPEAT     1084   1105       LRR 19.
FT   REPEAT     1106   1127       LRR 20.
FT   REPEAT     1129   1150       LRR 21.
FT   DOMAIN     1175   1422       PPM-type phosphatase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01082}.
FT   REGION     1076   1205       Interaction with SLC9A3R1.
FT                                {ECO:0000269|PubMed:21804599}.
FT   MOTIF      1715   1717       PDZ-binding; required for interaction
FT                                with SLC9A3R1.
FT                                {ECO:0000269|PubMed:21804599}.
FT   COMPBIAS      4      7       Poly-Ala.
FT   COMPBIAS     21     45       Poly-Ala.
FT   COMPBIAS    132    137       Poly-Ala.
FT   COMPBIAS    138    144       Poly-Ser.
FT   COMPBIAS    145    148       Poly-Ala.
FT   COMPBIAS    254    257       Poly-Ala.
FT   COMPBIAS    463    469       Poly-Pro.
FT   COMPBIAS   1682   1689       Poly-Gln.
FT   METAL      1210   1210       Manganese 1.
FT                                {ECO:0000250|UniProtKB:P35813}.
FT   METAL      1210   1210       Manganese 2.
FT                                {ECO:0000250|UniProtKB:P35813}.
FT   METAL      1211   1211       Manganese 1; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P35813}.
FT   METAL      1374   1374       Manganese 2.
FT                                {ECO:0000250|UniProtKB:P35813}.
FT   METAL      1413   1413       Manganese 2.
FT                                {ECO:0000250|UniProtKB:P35813}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     317    317       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     412    412       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1    512       Missing (in isoform 2).
FT                                /FTId=VSP_057809.
FT   VARIANT    1118   1118       S -> T (in dbSNP:rs9950585).
FT                                /FTId=VAR_056725.
FT   MUTAGEN    1715   1717       Missing: Loss of function in vivo, but
FT                                does not abolishes intrinsic phosphatase
FT                                activity. {ECO:0000269|PubMed:15808505}.
FT   CONFLICT    691    691       T -> A (in Ref. 5; BAA91980).
FT                                {ECO:0000305}.
FT   CONFLICT   1062   1062       L -> F (in Ref. 4; AAH47653).
FT                                {ECO:0000305}.
FT   CONFLICT   1083   1083       R -> S (in Ref. 2; BAA25532).
FT                                {ECO:0000305}.
FT   CONFLICT   1227   1227       D -> V (in Ref. 5; BAA91980).
FT                                {ECO:0000305}.
FT   CONFLICT   1490   1490       V -> M (in Ref. 4; AAH47653).
FT                                {ECO:0000305}.
FT   CONFLICT   1580   1580       Missing (in Ref. 4; AAH63519).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1717 AA;  184672 MW;  A4AB53F334EA8AB6 CRC64;
     MEPAAAATVQ RLPELGREDR ASAPAAAAAA AAAAAAAAAA LAAAAGGGRS PEPALTPAAP
     SGGNGSGSGA REEAPGEAPP GPLPGRAGGA GRRRRRGAPQ PIAGGAAPVP GAGGGANSLL
     LRRGRLKRNL SAAAAAASSS SSSSAAAASH SPGAAGLPAS CSASASLCTR SLDRKTLLLK
     HRQTLQLQPS DRDWVRHQLQ RGCVHVFDRH MASTYLRPVL CTLDTTAGEV AARLLQLGHK
     GGGVVKVLGQ GPGAAAAREP AEPPPEAGPR LAPPEPRDSE VPPARSAPGA FGGPPRAPPA
     DLPLPVGGPG GWSRRASPAP SDSSPGEPFV GGPVSSPRAP RPVVSDTESF SLSPSAESVS
     DRLDPYSSGG GSSSSSEELE ADAASAPTGV PGQPRRPGHP AQPLPLPQTA SSPQPQQKAP
     RAIDSPGGAV REGSCEEKAA AAVAPGGLQS TPGRSGVTAE KAPPPPPPPT LYVQLHGETT
     RRLEAEEKPL QIQNDYLFQL GFGELWRVQE EGMDSEIGCL IRFYAGKPHS TGSSERIQLS
     GMYNVRKGKM QLPVNRWTRR QVILCGTCLI VSSVKDSLTG KMHVLPLIGG KVEEVKKHQH
     CLAFSSSGPQ SQTYYICFDT FTEYLRWLRQ VSKVASQRIS SVDLSCCSLE HLPANLFYSQ
     DLTHLNLKQN FLRQNPSLPA ARGLNELQRF TKLKSLNLSN NHLGDFPLAV CSIPTLAELN
     VSCNALRSVP AAVGVMHNLQ TFLLDGNFLQ SLPAELENMK QLSYLGLSFN EFTDIPEVLE
     KLTAVDKLCM SGNCVETLRL QALRKMPHIK HVDLRLNVIR KLIADEVDFL QHVTQLDLRD
     NKLGDLDAMI FNNIEVLHCE RNQLVTLDIC GYFLKALYAS SNELVQLDVY PVPNYLSYMD
     VSRNRLENVP EWVCESRKLE VLDIGHNQIC ELPARLFCNS SLRKLLAGHN QLARLPERLE
     RTSVEVLDVQ HNQLLELPPN LLMKADSLRF LNASANKLES LPPATLSEET NSILQELYLT
     NNSLTDKCVP LLTGHPHLKI LHMAYNRLQS FPASKMAKLE ELEEIDLSGN KLKAIPTTIM
     NCRRMHTVIA HSNCIEVFPE VMQLPEIKCV DLSCNELSEV TLPENLPPKL QELDLTGNPR
     LVLDHKTLEL LNNIRCFKID QPSTGDASGA PAVWSHGYTE ASGVKNKLCV AALSVNNFCD
     NREALYGVFD GDRNVEVPYL LQCTMSDILA EELQKTKNEE EYMVNTFIVM QRKLGTAGQK
     LGGAAVLCHI KHDPVDPGGS FTLTSANVGK CQTVLCRNGK PLPLSRSYIM SCEEELKRIK
     QHKAIITEDG KVNGVTESTR ILGYTFLHPS VVPRPHVQSV LLTPQDEFFI LGSKGLWDSL
     SVEEAVEAVR NVPDALAAAK KLCTLAQSYG CHDSISAVVV QLSVTEDSFC CCELSAGGAV
     PPPSPGIFPP SVNMVIKDRP SDGLGVPSSS SGMASEISSE LSTSEMSSEV GSTASDEPPP
     GALSENSPAY PSEQRCMLHP ICLSNSFQRQ LSSATFSSAF SDNGLDSDDE EPIEGVFTNG
     SRVEVEVDIH CSRAKEKEKQ QHLLQVPAEA SDEGIVISAN EDEPGLPRKA DFSAVGTIGR
     RRANGSVAPQ ERSHNVIEVA TDAPLRKPGG YFAAPAQPDP DDQFIIPPEL EEEVKEIMKH
     HQEQQQQQQP PPPPQLQPQL PRHYQLDQLP DYYDTPL
//
